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Summary 
To study how MHC-associated self antigens may regulate the function ofT cells in the periph- 
ery, we generated CD8 + T  cell lines specific for a single residue variant of a self peptide. The 
self peptide (GAYEFTTL) was isolated from H-2-K  b class I MHC molecules immunopurified 
from tumor cells. CD8 + CTL lines from H-2  b mice were generated against  a variant peptide, 
pE4R,  (arginine for glutamic acid at the TCR contact position 4).  In short-term 51Cr-release 
assays, these CTL lysed H-2K  b targets that were pulsed with picomolar levels ofpE4R but did 
not lyse target cells coated with the self peptide at micromolar levels. However, in overnight 
assays the  CTL lysed Fas-positive target cells  in the presence of nanomolar levels of the self 
peptide. This kilting was shown to be entirely Fas/Fas ligand mediated by blocking with anti- 
Fas antibody and Fas-Fc chimeric molecules. While the selfpeptide was unable to induce serine 
esterase release from the CTL, it did induce secretion oflFN-% By these criteria then, the un- 
modified self ligand  served  as  a  partial  agonist  for the  CTL  raised  against  a  single-residue 
variant. CD8 + T  cell lines raised by in vitro stimulation with the selfpeptide were likewise un- 
able  to kill self peptide-coated targets via the  perforin pathway but did lyse targets via Fas. 
These and similar data from other groups show that self antigens  (i.e., MHC/peptide com- 
plexes) may be recognized by mature peripheral T cells. The T cell population is tolerant of the 
self antigen in the sense that they do not respond to physiological levels of the MHC/peptide 
complex. However, when the level of  self antigen is increased (by using synthetic peptide load- 
ing) CD8 + T cells may respond by proliferation, IFN-21 secretion, Fas ligand upregulation, and 
Fas-mediated  cytolysis  but  are  still  unable  to  respond  by  perforin-mediated  cytolysis  or 
granzyme release. The physiological significance of such partial activation in regulation of the 
immune system remains to be demonstrated. 
C 
D4  and CD8 + peripheral T  lymphocytes recognize 
and respond to foreign peptide antigens presented in 
the groove of MHC class II and class I molecules, respec- 
tively. Interaction of antigen-specific T cells with APC that 
present the original antigenic MHC/peptide complex usu- 
ally results in a cascade of T  cell responses including prolif- 
eration and secretion of a plethora of lymphokines in the 
case of CD4 + T  cells and proliferation, target cell lysis, and 
IFN-"/secretion by CD8 + T  cells (1, 2). 
Recent work  has  shown  that  T  cells  can  also  interact 
productively with  APC  expressing subtle  variants  of the 
original  agonist  MHC/peptide  complex.  Collectively, 
these less-than-optimal ligands have been referred to as "al- 
tered peptide ligands" (APL1; 3). In the initial studies, sin- 
gle-residue changes  made in  an  immunogenic peptide of 
hemoglobin presented by I-E  k molecules, resulted in a par- 
tial agonist APL that retained the ability to stimulate IL-4 
~Abbreviations used in  this paper: APL, altered peptide ligand; FasL, Fas 
ligand; MFI, mean fluorescence  intensity. 
secretion but  not  proliferation by a  Th2  clone  (4).  This 
work was  followed by numerous reports  of variations in 
the  original  MHC/peptide  ligand  resuking  in  a  partial 
stimulation of CD4 + T  cell responses (5-8). Other studies 
demonstrated that APL could inhibit the response of CD4 § 
or CD8 +  T  cells  to  their original  agonist ligands  (9-13). 
The antagonist MHC/peptide ligand was shown to interact 
specifically with the TCR in a way that disrupted the sig- 
naling provided by the agonist ligand. 
Only recently have attempts been made to ask whether 
APL, serving as non-optimal ligands for the TCR, exist en- 
dogenously in a healthy animal and whether they may in- 
fluence the function of T  cells. Using TC1L transgenic ani- 
mals,  it has been shown that during CD8 § T  lymphocyte 
positive selection in  the  thymus,  antagonist peptides  (14) 
and other APL (15) serve as highly efficient ligands  for sig- 
naling this maturation step while agonist ligands usually tip 
the balance to deletion or inactivation of maturing T  cells 
(16). These studies have fostered the notion that the multi- 
tude ofselfpeptides presented by selfMHC on thymic epi- 
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thymocytes for which they serve as low-affinity ligands for 
the newly expressed TCR. But what about the influence of 
selfpeptides on mature, peripheral T  cells (17,  18)? 
T  cells that react with self antigen with high affinity are 
deleted during thymus maturation if the self antigen has ac- 
cess to the thymus. In some cases, where antigen is present 
only in the periphery, the reactive T  cells may enter a state 
ofanergy (19, 20). However, not all self-reactive T  cells are 
deleted or  anergized and  healthy individuals may  contain 
such  autoreactive  cells  (21,  22).  Whether  such  a  cell be- 
comes autoaggressive may depend on the APC it encoun- 
ters, the amount and tissue distribution of the antigen, and 
the presence locally of certain cytokines and adhesion mol- 
ecules.  Given the abundance  of self peptides presented by 
MHC  molecules  in  vivo  and  the  promiscuity  of TCR/ 
ligand interactions, it is possible that T  cells stimulated by 
foreign  antigen  may  encounter  self  APL.  In  terms  of 
whether peripheral T  cells can coexist with APL in vivo, a 
recent study demonstrated that in a TCRJ3 chain transgenic 
mouse,  the response to a variant hemoglobin peptide pre- 
sented by I-E  k could be antagonized in vitro with the self 
hemoglobin peptide known to be widely presented in the 
animal (23). In this case, natural peripheral T  cells coexisted 
with a peripherally expressed antagonist ligand. In a CD8 + 
system, Cao et al. showed recently that a H-2Kd-restricted 
CTL clone specific for an influenza hemagglutinin peptide 
could also recognize and lyse cells coated with a myeloma- 
derived immoglobulin VH "self" peptide (24). As it turned 
out,  the  gemlline sequence  of the  self peptide differed in 
one position from the myeloma VH sequence and this ger- 
mline selfpeptide acted only as a partial agonist. In this case 
the  self ligand  induced  Fas-mediated  but  not  pefforin- 
mediated cytolysis of targets.  The  in vivo presentation of 
this self Ig VH peptide has not been studied. 
We set out to study whether known selfpeptides that are 
presented in the MHC  groove would be recognized by pe- 
ripheral T  cells. We found  that  a  self antigen can act as a 
partial agonist ligand for CD8 +  T  cells, at least when  the 
level ofpeptide expression on the APC is high. 
Materials  and Methods 
Animals.  Adult female C57BL/6 mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME) and used at 6-8 wk of age. 
Cell Lines.  RMA-S (H-2b), EL-4 (H-26), MC57G (H-2b), P815 
(H-2a), and Jurkat (human T  cell line) cells were maintained in 
RPMI 1640 supplemented with 10~  heat inactivated FCS, 2 mM 
t-glutamine, and antibiotics (RP10). The cell line RMA-S/B7, a 
kind gift of Dr. Matteo Bellone (Laboratorio I. A., Instituto Sci- 
entifico H. San Raffaele, Milan, Italy), is stably transfected with a 
cDNA encoding the human B7.1 molecule (25). The human cell 
lines Jurkat-K  b and T2-K  b were  obtained from Peter Cresswell 
(Yale  University, New Haven,  CT).  P815-K  6 and P815-D  b are 
transfectants  expressing the  mouse  H-2K  6 or H-2D  b gene  (26). 
The transfectants  were maintained in RP10  containing G418 at 
0.4 mg/ml. 
mAbs.  The following mAbs were used: Y3 (anti-H-2K6; Amer- 
ican Type  Culture  Collection, Rockvilte, MD),  3.168.8  (anti- 
CD8; PharMingen, San Diego, CA), L3T4 (anti-CD4; PharMin- 
gen),  7D4  (anti-CD25,  IL-2  receptor  a,  clone;  PharMingen), 
anti-CD44  (PharMingen),  H57-597  (anti-TCR  cl~;  Pharmin- 
gen). JO2  (anti-mouse Fas;  PharMingen)  was provided by Dr. 
P.J.  Fink  (University  of Washington,  Seattle,  WA).  The  anti- 
human Fas mAb M3 (blocking antibody), M33 (control antibody, 
non-blocking), and the fusion protein Fas.Fc (27) were kind gifts 
of Dr. David Lynch (Immunex Research and Development Cor- 
poration, Seattle, WA). The anti-Fas ligand (FasL) antibody PE62 
was kindly provided by Dr. Jorg Tschopp  (University of Laus- 
sane,  Switzerland) (28). To study FasL expression, 105 CTL were 
cultured for 16 h with PMA (10 ng/ml) and ionomycin (500 ng/ 
ml) or with 104 MC57G cells coated with  1 p~M peptide. Cells 
were stained with PE62 followed by FITC-conjugated sheep anti- 
rabbit Ig (Accurate Chemicals and Scientific Corp., Westbury, NY). 
Peptides.  The  40-kD  peptide  (GAYEFTTL)  and  its single- 
amino acid variants pE4R (GAYRFTTL), pE4K (GAYKFTTL), 
pE4Q (GAYQFTTL) and pE4D (GAYDFTTL) were synthesized 
using a Synergy peptide synthesizer (Applied Biosystems; Foster 
City, California) and analyzed by HPLC. Peptide concentrations 
were determined using the BCA assay (Pierce Chemical Co., Rock- 
ford, IL). The Kh-binding OVA (SIINFEKL) and the Db-binding 
influenza (ASNENMDAM) peptides were described previously (16). 
RMA-S Stabilization Assay.  RMA-S  cells were incubated at 
31~  overnight to provide maximum MHC expression at the cell 
surface (29). Various concentrations ofpeptide were added for 30 
min at 31~  and cultures were washed and shifted to 37~  for 
another  4  h.  Cells were  washed  and stained for K  b expression 
with anti-K  b antibody Y3 followed by FITC-conjugated goat anti- 
mouse IgG (Cappel, Malvem, PA). 
In  Vitro Priming of Cytotoxic Lymphocytes.  RMA-S/B7 cells were 
cultured at  31~  overnight in  RP10  medium  and pulsed with 
100 p,M peptide for 1 h at 31~  Cells were then washed, irradi- 
ated (20,000 rad), and 5 X  106 peptide-putsed cells were cultured 
with 50  ￿  106 spleen cells from naive mice in  10  mt medium. 
Medium used was RP10.  One-half of the culture medium was 
changed daily. At day 5  cells were tested for cytolytic activity. 
Cells were restimulated weekly with irradiated spleen cells coated 
with 1 p,M peptide and maintained in the presence of 5% rat Con 
A supernatant. 
CTLAssays.  Target  cells  were  labeled with  [S~Cr]-sodium 
chromate in R.P10  for 1 h at 37~  After washing, cells were in- 
cubated with peptide at the indicated concentration for another 
hour, washed three times, and 104 cells were transferred to a well 
of a  round-bottomed  96-well plate.  Varying numbers  of CTL 
were added to give a final volume of 200 p,1. The plates were in- 
cubated for 4 or 18 h at 37~  as indicated. At the end of the as- 
say,  the plates were centrifuged and supernatants  (100  p,1/well) 
were harvested and counted in a  gamma counter.  The percent 
specific lysis was calculated as: 100￿  (experimental release-spon- 
taneous release/maximal release-spontaneous release).  Spontane- 
ous and maximal release were determined in the presence  of either 
medium or 1% Triton X-100, respectively. Spontaneous release 
after 4 h was 10-15%, after 18 h was 25-38%. For titration exper- 
iments, peptide was titrated before the addition of target and effector 
cells.  In some cultures emetine (0.6  p~g/ml),  anti-huFas M3  (10 
p~g/ml),  M33  (10  I~g/ml),  or human  Fas.Fc (15  p~g/ml)  were 
added, as noted. The presence of the anti-Fas (M3, M33) or Fas.Fc 
had no effect on the spontaneous release of any of the target cells. 
Proliferative Response.  To  measure  the  proliferative response, 
105 to 103 CTL,  10 d after their last restimulation, were cultured 
in flat-bottom 96-well plates with 7 ￿  10  s irradiated spleen cells 
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[3H]-TdiL and harvested after 16 h.  Data represent the mean of 
triplicate cultures. SD were generally within 5-15% of the mean. 
Serine Esterase Assay and IFN-3' ELISA.  EL-4 cells were irra- 
diated (20,000 rad) and then coated with 1 ~M peptide for 1 h at 
37~  104 washed cells were added to a well of a 96-well plate 
containing 2 ￿  105 CTL. After 16 h 80 I~1 of the supernatant was 
assayed for IFN-"/content and 20 Ixl supematant was analyzed for 
BLT serine esterase activity as described (10). Briefly, 20 Ixl of the 
supernatant was mixed with 180  ~1 of reaction buffer, containing 
2  ￿  10  -4 M  N-benzytoxycarbonyl-r-lysine thiobenzyl ester and 
2.2 ￿  10  -4 M 5,5'-dithio-bis-2-nitrobenzoic  acid in PBS, pH 7.4. 
After incubation for 2 h, the absorbance was measured at 405 nm 
using an ELISA plate reader. The percentage serine esterase  re- 
lease was determined following the formula used for the CTL ly- 
sis assay. 
The peptide-induced IFN-'y production by the CTL was de- 
termined  using  a  commercially available IFN-~/ ELISA  (Gen- 
zyme, Cambridge, MA; sensitivity 125  pg/ml). All experiments 
were done in quadruplicate. 
RT-PCR.  For assessment  of FasL expression by PCIL, 5  ￿ 
106  CTL  were  mixed  with  1  ￿  105  irradiated MC57G  cells 
coated with 1 txM peptide in 24-well plates. After 6 h incubation, 
total RNA was isolated from the T cell lines using RNA STAT- 
60 reagent (Tel-Test "B",  Inc., Friendswood, TX).  For reverse 
transcription, 1 Ixg of total cellular RNA was added to 25 ml of 
reverse transcription buffer containing 0.4 IxM oligo-dT (12-18), 
1 mmol/1 dNTP  (dATP, dCTP, dTTP,  dGTP),  1 Ixl of Super- 
script II ILNaseH- reverse transcriptase (GIBCO BILL, Gaithers- 
burg,  MD),  and  40  units  ILNasin  (Promega  Corp.,  Madison, 
WI). After incubation at 42~  for 1 h, 2 I~1 of the sample was sus- 
pended in 50 ml PCIL-buffer containing 0.3  I~g of each primer 
and 2 units Taq DNA polymerase (Promega). PCIL was carried 
out with a Thermal cycler (Perkin-Elmer Corp., Norwalk, CT) 
programmed for denaturation at 94~  for 90 s, annealing at 50~ 
for 90 s and extension at 72~  for 90 s. Primers were devised from 
published  sequences.  Fas  ligand:  5'-CGTGAGTTCACCAAC- 
CAAAGC  (FasLs, sense),  5'-GAGTTCCTCATATAGACCTTG 
(FasLas, antisense)  (30); glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH)  :5'-CCATCACCATCTTCCAGGAG  (GAPDHs, 
sense),  5'-CCTGCTTCACCACCTTCTTG  (GAPDHas,  anti- 
sense)  (31). 
8  I~g of reaction product was  run  on  a  2%  agarose gel and 
stained with ethidium bromide. RNA integrity was checked by 
reverse transcription and PCIL with primers for GAPDH.  The 
origin of the amplified product was confirmed by direct sequenc- 
ing of the PCIL product using Sequenase Version 2.0 DNA se- 
quencing kit (USB; Amersham Corp., Arlington Heights, IL). 
To permit quantitative analysis of PCIL signal strength, primer 
and ILNA concentrations, as well as PCR cycles, were titrated as 
described (32). PCIL comprised 24 cycles for GAPDH and 27 cy- 
cles for FasL. 
Results 
Induction of CTL Against a Self Peptide Variant.  The  sequence 
GAYEFTTL was identified as a naturally processed peptide 
isolated from H-2K  b molecules purified from LB 27.4 cells 
(33).  It has homology to a bacterial 40-kD ribosomal pro- 
tein  and  is referred  to  as  the  40-kD  peptide  (Imaeda,  S., 
and C.A. Janeway, personal commununication). As would 
be  expected of a  naturally presented peptide,  it efficiently 
binds  and  stabilizes H-2K  6  (14).  Structural analyses of K b 
complexed with single peptides indicate that the side chain 
of position 4  of an octameric peptide points up, out of the 
K b groove  (34,  35).  To study the H-2Kb-restricted CD8 + 
T  cell response to a self peptide and its single-residue vari- 
ants, we therefore made a number of analogues of the 40- 
kD peptide with substitutions at position 4.  The RMA-S 
stabilization data presented in Fig.  1  show that the 40-kD 
peptide and all position four variants bind K b at least as well 
as another Kb-presented epitope from Ova (SIINFEKL). 
The analogue peptide pE4R. was used to induce a C57BL/6 
CTL  response  in  vitro  using RMA-S  cells expressing the 
B7 costimulator molecule as APC. After a number of weekly 
stimulations the line  demonstrated peptide-specific killing 
of target cells that was entirely H-2K  b restricted (Fig. 2 A). 
This uncloned CD8 §  T  cell line is referred to as CTL.R. 
In a  4-h.  SlCr-release assay using EL4  cells as targets and 
high doses ofpeptide, the CTUR  line showed some cross- 
reactive lysis of targets coated with the pE4Q variant, but no 
lysis of targets coated with pE4K, pE4D,  or wild-type, 40- 
kD peptide (Fig. 2 B). Consistent with this result, only pE4Q 
and the immunizing peptide, pE4R induced serine esterase 
release by the  CTL.R  line when  EL4  cells coated with  1 
~M levels ofpeptide were used as stimulators (Fig. 3). 
Lysis of Fas-positive Targets.  The  CTL.R  line  exhibited 
a  different pattern of cytolytic specificity when target cells 
expressing Fas were used in an 18-h SlCr-release assay. With 
Jurkat-K  b cells as targets it was  evident  that  coating with 
the 40-kD peptide at 10-9M or higher concentrations sensi- 
tized the  cells for lysis (Fig. 4).  Lysis mediated by the in- 
ducing,  pE4R  peptide  occurred  at  10-ilM  concentrations 
in this assay. This cross-reaction on 40-kD was specific since 
the pE4K and pE4D peptides caused no lysis of the Jurkat- 
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Figure  1.  Position 4 variants ofa selfpeptide bind and stabilize  K b  on 
RMA-S cells. The RMA-S stabilization assay was performed to analyze 
binding of the peptides to the K  b molecule. RMA-S cells were incubated 
with various peptide concentrations at 31~  and the level of K  b on the 
cell surface was determined by FACS  |  analysis. The mean fluorescence 
intensity (MFI) is shown. Flu refers to a control D  b binding peptide from 
influenza nucleoprotein. 
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Figure 2.  MHC and peptide specificity  of the in vitro-induced CTL.R 
line. Mouse and human tumor cell lines were coated with 1 I~M of the 
pE4R peptide and used as targets (A). EL-4 cells were coated with 1 ~M 
of the 40-kD peptide or its variants  and used as targets (13). 
Figure 3.  Serine  esterase release by CTL.R is induced after stimulation 
with pE4R and pE4Q peptides. CTL.R was cultured  with irradiated  EL-4 
cells coated with 1 ~tM of the self-peptide or its variants and serine es- 
terase release was determined  after 16 h. The assay was conducted in qua- 
druplicate and error bars show the means and standard deviations. 
ence of emetine inhibited the lysis ofJurkat-K  b cells coated 
with the 40-kD peptide by CTL.R  (Fig 5 A),  whereas it 
had only a modest effect on the CTL.R mediated cytotox- 
icity of targets coated with pE4R (Fig. 5 B). 
Self Peptide Induction of Proliferation and IFN-  y  Secretion by 
CTL.R.  The 40-kD selfpeptide was able to stimulate the 
K b targets. Jurkat cells express high levels of the Fas mole- 
cule (CD95)  on their surface as detected by staining with 
the M33  antibody (25,  and data not shown). MC57G fi- 
broblast cells from C57BL/6 mice can also retain 51Cr well 
enough to be used in an  18-b SlCr-release assay,  and are 
Fas-negative. The data in Table 1 show that MC57G cells 
are not damaged by the CTL.R. line when coated with the 
40-kD peptide, but they are  lysed efficiently in the pres- 
ence of the pE4R peptide. 
Definitive evidence  that  the  CTL.R-mediated lysis  of 
Jurkat-K  b cells coated with the self peptide was Fas-medi- 
ated was obtained in blocking studies. The data presented 
in Fig. 5 A  show that the 40-kD peptide-induced lysis of 
Jurkat-K  b  targets  can be  completely blocked by  the  M3 
mAb specific for human Fas whereas the control M33 mAb 
had no effect.  Furthermore, addition of a  Fas.Fc chimeric 
molecule to the assay completely blocked the self peptide- 
mediated lysis ofJurkat-K  b (Fig.  5  A).  In contrast to this, 
the blocking mAb M3 and the Fas.Fc showed no significant 
inhibition  of the lysis ofpE4R-coated target cells (Fig. 5 B). 
Fas/FasL-mediated killing has been shown to require mac- 
romolecular synthesis for effector cell activation and to be 
sensitive to inhibition of protein synthesis, for example by 
emetine (36, 37).  In line with this, we show that the pres- 
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Figure  4.  Fas  + target cells coated with the self-peptide are lysed in a 
18 h SlCr-release  assay by CTL.R. SlCr-labeled  Jurkat-Kb  ceils were incu- 
bated with the indicated concentrations  of the 40-kD self peptide or its 
analogs and used in a 18 h Cr-release assay as described in Materials and 
Methods. CTL were added at an E:T ratio of 10:1. 
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Coated with the Self Peptide 
MC57G targets  Jurkat-K  b targets 
%StCr-release  at E:T 
Peptide  10  3.3  1.1  0.4  10  3.3  1.1  0.4 
None  16  10  8  7  21  18  13  9 
pE4fk  71  53  34  17  88  40  38  29 
40 kD  14  11  8  7  57  34  27  14 
SlCr-Labeled Jurkat-K b cells  (Fas-positive)  and fihrosarcoma  cell  line 
MC57G (Fas-negative)  were coated with 1 ~M of the 40-kD self-pep- 
tide or the cognate  pE4R peptide and used as targets  in an 18-h  SlCr- 
release assay. 
proliferation  of the  CTL.lq.  fine  in  a  3-d  3H-TdR  assay 
(Fig.  6 A).  The self peptide was about one-tenth as effec- 
tive as the pE4R peptide, and approximately equivalent to 
the pE4Q peptide in this stimulation. The other position 4 
variant peptides had no capacity to stimulate in this assay. 
Despite the fact  that the 40-kD  self peptide was unable 
to stimulate the release of serine esterase from CTL.tL (Fig. 
3),  these  same  supematants  did show the presence  of se- 
creted IFN-~/(Fig. 6 B). Again, the 40-kD and pE4Q were 
about  equally  effective  in  stimulating  IFN-~/  secretion 
whereas pE4K and pE4D were ineffective. 
Induction of CTL against the 40-kD Self Peptide.  Repeated  in 
vitro stimulation ofC57BL/6 splenocytes with RMA-S/B7 
cells coated with the 40-kD selfpeptide resulted in the pro- 
duction of a CD8 + line referred  to as CTL.40kd.  FACS | 
analysis of this line and the CTL.R. line showed that both ex- 
pressed equivalent levels ofCD8, TCR, and CD44, whereas 
the CTL.40kd had slightly higher levels of CD25  (IL2tLa) 
expression (data not shown). 
The CTL.40kd line mediated no peptide-specific lysis of 
any target cell in a 4-h 51Cr-release  assay (data not shown). 
However, in an 18-h assay, with Jurkat-K  b targets, the 40-kD 
peptide induced specific  51Cr-release at nanomolar and higher 
concentrations  (Fig.  7).  None  of the  four  analogue  pep- 
tides,  including pE4IL,  was  able  to  stimulate  cytotoxicity 
(Fig. 7). The 40-kD directed lysis ofJurkat-K  b was entirely 
Fas-dependent since no lysis  of Fas-negative MC57G  tar- 
gets could be detected (Table 2) and the lysis  ofJurkat-K  b 
was blocked completely by the M3 antibody, by the Fas.Fc 
chimera, and by emetine (Fig. 8). 
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Figure 5.  The cytotoxic activity of CTL.R targeted by the 40-kD pep- 
tide is entirely Fas/FasL mediated. S*Cr-labeledJurkat-Kb  cells were coated 
with 1 p,M of the 40-kD self-peptide (A) or the cognate pE4K peptide (/3) 
and used as targets in an 18 h 51Cr-release assay. Emetine (0.6 I~g/ml), anti- 
huFas M3  (10 I~g/ml), M33  (10  p,g/ml),  or human Fas.Fc  (15 I~g/ml) 
were added, as noted. 
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Figure 6.  Proliferative response and IFN-'y production by CTL.R after 
stimulation with the selfpeptide or its variants,  t0 d aKer their last restim- 
ulation, CTL.K cells were cultured in 96-well plates with irradiated spleen 
cells plus 1 p,M peptide  (A). The induced IFN- 3, release  was assayed  in 
supematants from cultures  following 16 h stimuhtion with irradiated EL-4 
cells coated with 1 IxM peptide (B). 
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Figure  7.  CTL.40kd  lysis of Fas-positive  Jurkat-K  b cells coated with 
the self-peptide in an 18 h SlCr-release assay, sICr-labeled  Jurkat-K  b  cells 
were incubated with the indicated concentrations  of the 40-kD self pep- 
tide or its analogs and used in an 18 h SlCr-release assay. CTL were added 
at an E:T ratio of 15:1. 
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Table 2.  Only Fas  + Targets Are Lysed by CTL. 40kd when 
Coated with the Self Peptide 
MC57G targets  Jurkat-K  b targets 
%SlCr-release at E:T 
Peptide  15  5  1.6  3.3  15  5  1.6  3.3 
None  11  9  7  6  17  12  11  9 
40 kD  13  10  7  5  50  25  19  12 
SlCr-labeled Jurkat-K  b cells (Fas-positive) and fibrosarcoma cell line 
MC57G (Fas-negative)  were coated with I I~M of the 40-kD self-pep- 
tide and used as targets in an 18-h SlCr-release  assay. 
As would be expected, the 40-kD peptide that was used 
to derive the CTL.40kd line was able to specifically induce 
proliferation of the  line  (Fig.  9  A).  Whereas  the  40-kD 
peptide  was  unable to  induce serine esterase  release from 
the CTL.40kd line (data not shown), it was able to induce 
high levels of IFN-~/secretion (Fig. 9  B). 
Induction  of Fas Ligand Expression.  We have shown that 
the  lysis  of Jurkat-K  b targets  by the  CTL.R line and the 
CTL.40kd line in the presence of the self peptide is depen- 
dent on the  Fas  molecule expressed  on the  target cells.  It 
seemed likely therefore that this peptide can induce surface 
expression of FasL on the  CTL. We used a semiquantita- 
tive RT/PCR  technique to show that the 40-kD self pep- 
tide  (and the pE4R peptide in the  case  of CTL.R), were 
able to upregulate FasL mRNA  expression (Fig.  10).  Co- 
culture with PMA and ionomycin was  used as  a  positive 
control for the stimulation of the CTL. In addition to this 
PCR study, we examined the induction of FasL expression 
on the cell surface using a polyclonal rabbit antiserum (Fig. 
11).  In the case of the CTL.R, the cognate peptide, pE4R, 
and the self peptide  clearly induced FasL expression on a 
fraction of the cells. Similarly, in the case  of the CTL.40kd 
line, the selfpeptide was able to induce FasL expression on 
a fraction of the cells. Even in the case of PMA/Iono stim- 
ulation only a fraction of the cells were FasL  + at this 12-h 
timepoint. We  do  not know why only a  fraction  (up  to 
50%) of the cells in these CTL lines stain positively for FasL 
expression.  Conceivably FasL  expression is  cell cycle  de- 
pendent and has a short half-life on the cell surface. 
0" 
e4. ~"  r  ~,,-  .~*~ 
x 
Figure 8.  The 40-kD peptide activates only the Fas lytic pathway in 
CTL 40 kD. SlCr-labeled  Jurkat-K  b cells were coated with 1 IxM of the 
40-kD self-peptide  and used as targets in an 18 h S  lCr_release assay. Eme- 
tine (0.6 ~g/ml), anti-huFas  M3 (10 I~g/ml),  M33 (10 txg/ml), or human 
Fas.Fc (15 ~g/ml) were added, as noted. CTL.40kd were added at an E:T 
ratio of 15:1. 
Discussion 
We generated a polyclonal CD8 + T  cell line by in vitro 
stimulation with  a  single residue variant of a  self peptide 
presented by the H-2K  b molecule. This line, CTL.R, was 
able to lyse Fas  + and Fas- target cells that were coated with 
the immunizing peptide, pE4R. A  full spectrum of CD8 + 
T  cell responses was elicited by pE4R, including: perforin- 
mediated cytolysis, proliferation, serine esterase release,  IFN-'y 
secretion, FasL upregulation and Fas-mediated cytolysis of 
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Figure 9.  Stimulation of CTL.40kd with the self peptide induces pep- 
tide-specific  proliferation (.4) and IFN-y production (B). The IFN-y pro- 
duction and proliferative  response by CTL.40kd were assessed  as described 
in Materials and Methods and Fig. 6. 
targets. When APC were coated with the 40-kD  self pep- 
tide, no lysis of Fas-negative targets was obtained with CTL.R 
even  at  micromolar levels of peptide  addition.  However, 
with Fas  § Jurkat-K  b cells as targets, the 40-kD peptide in- 
duced cytolysis. Whereas approximately picomolar levels of 
the original antigenic pE4R targetedJurkat-K  b for lysis, na- 
nomolar levels of the selfpeptide were required to observe 
lysis. Although the self peptide, acting as an APL for CTL.R, 
was not able to stimulate perforin-mediated cytolysis or serine 
esterase  release,  it  was  able  to  stimulate  the  secretion  of 
IFN-~/and proliferation in addition to FasL surface expres- 
sion and Fas-mediated cytolysis. 
The 40-kD peptide was isolated from the groove ofH-2K  b 
molecules prepared from LB 27.4  cells. However, LB 27.4 
cells, which do express Fas, were not targets for the CTL.R 
line (data not shown). Thus, whereas at the higher levels of 
ligand density achieved  by  synthetic  peptide  loading,  the 
self peptide acts as a partial agonist for the CTL, at the en- 
dogenous  level of presentation  this  ligand is  not  stimula- 
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Figure  10.  The  40-kD  self peptide  induces  upregulation  of FasL 
mRNA expression in CTL.R and CTL.40kd. 5 ￿  106 CTL were incu- 
bated with 10  s irradiated MC57G cells alone or coated with 1 I~M pep- 
tide, or were stimulated with PMA/ionomycin. After 6 h, total RNA was 
isolated and 23 cycles of amplification using primers specific for GAPDH 
or 27 cycles for FasL were performed. PCR products were run on a 2% 
agarose gel and visualized  by ethidium bromide staining. Lane 1, 100-bp 
ladder marker; lane 2, CTL.R +  pE4R peptide; lane 3, CTL.R +  40-kD 
peptide; lane 4, unstimulated CTL.R; lane 5, CTL.40kd  +  40-kD pep- 
tide;  lane  6,  unstimulated  CTL.40kd;  lane  7,  MC57G  cells; lane  8, 
CTL.40kd  +  PMA/ionomycin; lane 9, CTL.R  +  PMA/ionomycin; lane 
10, no cDNA control. 
tory.  We  do  not  have  biochemical proof for  the  in  vivo 
presentation of the 40-kD  peptide by B  cell, or any other 
cell type in  vivo.  Since  the  sequence  was  isolated from  a 
tissue  culture-maintained B  cell line,  it  could represent  a 
mutation.  We consider this to be quite unlikely, especially 
since the 40-kD sequence has unique properties in the way 
it interacts with CD8 + T  cells from B6 mice. Thus, whereas 
a number of  single-residue variants (pE4R and pE4Q) readily 
induce  perforin-mediated  cytolysis,  the  40-kD  peptide 
does not. 
These  results  complement  those  recently presented  by 
Cao et al., who reported that a germline VH peptide acted 
as a partial agonist for a  hemagglutinin-specific CTL clone 
(24).  In that  case Fas-mediated cytolysis of peptide-coated 
targets, could be selectively induced by a germline V.  pep- 
tide. It is apparent from these two reports that CD8 + lym- 
phocytes,  like  CD4 +  lymphocytes,  can  give  partial  re- 
sponses to APL. 
To follow up on our finding that the CTL.R line treated 
the  40-kD  as a  partial agonist,  we  used  the  same in vitro 
stimulation protocol to generate a CTL line using the 40-kD 
self peptide as the  immunogen.  A  CD8 +  line, CTL.40kd, 
grew out slowly and responded to the immunizing peptide 
as if  it were a partial agonist. Thus, the 40-kD peptide at high 
concentration  stimulated FasL upregulation,  Fas-mediated 
killing and IFN-~/secretion but not perforin-mediated kill- 
ing or serine esterase release. Despite their similar response to 
the 40-kD peptide, the T  cells in the CTL.40kd line had a Fluonescence intensity Oog) 
Figure 11.  Induction of FasL expression on the cell surface. FasL ex- 
pression on stimulated and unstimulated CTL was analysed using a poly- 
clonal antibody PE62. CTL.R (A-D) and CTL.40kd (E-G) were stimu- 
lated with  1 ~M  peptide  coated, irradiated MC57G  cells or  PMA/ 
ionomycin for 12 h. Cells were stained with PE62 followed by sheep 
anti-rabbit lgG coupled to FITC. (A) Unstimulated CTL.R, (B) CTL.R 
stimulated with pE4R peptide, (C) CTL.R stimulated with 40-kD pep- 
tide, (D) CTL.R stimulated with PMA and ionomycin, (E) unstimulated 
CTL.40kd, (F) CTL 40-kD stimulated with 40-kD peptide, (G) CTL.40kd 
stimulated with PMA and ionomycin. 
different fine specificity from the CTL.R line raised against 
the pE4R peptide: whereas the former showed no cross-reac- 
tivity on pE4R  or any of the  other position  4  variants  in 
any T  cell assay, the latter did show such cross-reactivity. 
The  simplest  explanation  for partial  signaling  of CD4 + 
or CD8 + T  cells by APL is that these ligands (in association 
with MHC) have a lower affinity for the TCR  than do full 
agonist  ligands.  A  model  by  which  the  presumed  small, 
quantitative  differences  in  the  TCR  affinity for its  ligand 
may translate into what appear to be qualitatively different 
signaling outcomes  has recently been proposed,  and is re- 
ferred to as a kinetic proofreading (38) or kinetic (39) model 
of TCR  signaling.  According to this, a number of sequen- 
tial, time-consuming steps are required to assemble the full 
agonist signaling complex that include clustering receptors, 
phosphorylation,  SH2 interactions,  and further phosphory- 
lations,  etc.  At  each  step  of this  cascade  the  TCR/ligand 
complex may dissociate  making it very unlikely that low- 
affinity ligands  can  ever assemble the  final  signaling  com- 
plex.  However,  a  high  density  of low  affinity ligands  can 
support the early steps of the process and lead to a distinct 
signaling  pathway.  Biochemical  distinctions  in  TCR  sig- 
naling have recently been reported in T  cell clones recog- 
nizing agonist versus partial agonist ligands  (40,  41).  In the 
case  of the  40-kD  peptide  presented  by the  K b molecule, 
one may postulate  that all of the  high affinity TCRs  have 
been  deleted  from the  T  cell repertoire.  However,  CD8 + 
T  cells bearing  TCRs  that recognize  this  self ligand  with 
low  affinity  still  persist  in  the  animal.  When  confronted 
with the self antigen expressed at a high density on APC as 
a result of exogenous peptide loading, these T  cells can re- 
spond by proliferation,  FasL expression and IFN-~/release. 
The  constitutive  level of expression  of the  40-kD  peptide 
ligand does not trigger even these responses. Therefore, the 
T  cells could be thought of as fully tolerant to endogenous 
levels of expression.  Whether  this  type of partial  response 
ofCD8 § T  cells to selfligands, the expression of which has 
been upregulated, has any significance to the lymphoprolif- 
erative disease observed in Fas- and FasL-deficient  animals 
is not known. 
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